Creativ-Ceutical to be Centre Stage at ISPOR Europe 2010
Summary
Paris, France, October 13, 2010 --( 3 podium presentations (Patient access schemes in UK are driven by Health Technology Assessment; Influence of HTA and hospital funding systems on patient access to innovating medicines: example of advanced renal cell cancer in Western Europe; Huntington quality of life interview (HQOLI): a new Huntington disease specific quality of life instrument) 1 workshop (How to address regional market access hurdles in decentralized European countries) 1 issue panel (Rare (Orphan) disease: tension between government support of developing new therapies and reimbursement processes?Perspectives from EU-5 (Germany, UK, France, Spain and Italy), Central East Europe, USA and Canada) 8 posters (Impact of methodological choices and assumptions in economic evaluations of rotavirus vaccination; Value of congress abstracts of cost-effectiveness studies for decision makers; Market access agreements in Europe: typology and rationale; Healthcare organizations/services clustering: example of PCTs in England; European-HD burden study (Euro-HDB) – preliminary results for Italy and France; Quality of life of caregivers in Huntington’s disease – first results from Euro-HDB study; Utilization of antiemetic prophylaxis alongside chemotherapy in four European countries; Cost-effectiveness of memantine in the treatment of moderate to severe alzheimer’s disease patients with agitation, aggression and psychosis – the UK example) “Two years after set-up, the company has contributed to many works and publications, and the ISPOR Congress is a great occasion for us to showcase our expertise.This year Creativ-Ceutical will have its own booth and we will be pleased to discuss our various posters and presentations as well as future collaboration and partnerships,” said Steven Flostrand, Business Development Director.Contact Odile Barthez, Communications Manager Tel +352 2020 2406 Email oba@creativ-ceutical.com Website www.creativ-ceutical.com ### Paris, France, October 13, 2010 --( PR.com )-- In addition to an exhibition stand, the company will also actively present and debate on the following:3 podium presentations (Patient access schemes in UK are driven by Health Technology Assessment; Influence of HTA and hospital funding systems on patient access to innovating medicines: example of advanced renal cell cancer in Western Europe; Huntington quality of life interview (HQOLI): a new Huntington disease specific quality of life instrument)1 workshop (How to address regional market access hurdles in decentralized European countries)1 issue panel (Rare (Orphan) disease: tension between government support of developing new therapies and reimbursement processes?Perspectives from EU-5 (Germany, UK, France, Spain and Italy), Central East Europe, USA and Canada)8 posters (Impact of methodological choices and assumptions in economic evaluations of rotavirus vaccination; Value of congress abstracts of cost-effectiveness studies for decision makers; Market access agreements in Europe: typology and rationale; Healthcare organizations/services clustering: example of PCTs in England; European-HD burden study (Euro-HDB) – preliminary results for Italy and France; Quality of life of caregivers in Huntington’s disease – first results from Euro-HDB study; Utilization of antiemetic prophylaxis alongside chemotherapy in four European countries; Cost-effectiveness of memantine in the treatment of moderate to severe alzheimer’s disease patients with agitation, aggression and psychosis – the UK example)“Two years after set-up, the company has contributed to many works and publications, and the ISPOR Congress is a great occasion for us to showcase our expertise.